Tag: European
Gains in tRNAslation: It’s time for investors to realize the potential...
“The original is unfaithful to the translation,” — Jorge Luis Borges
Investing in new innovative RNA technologies can lead to rapid value creation, and Europe...
Agios’ Tibsovo has an FDA green light in AML. Why did...
Agios may have persuaded the FDA into doling out an approval for its acute myeloid leukemia (AML) drug Tibsovo based on phase 1 results,...
With U.S. elections nearing, European pharma giants brace for potential pricing...
With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections. The races could affect European pharma...
Unlike FDA, European regulators refuse to clear chloroquine for COVID-19 without...
Chloroquine and hydroxychloroquine have drawn more attention—and certainly more presidential support—than any other drug during the global quest to find an effective coronavirus therapy.
Now, days after...
